---
title: EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors
nct_id: NCT06769165
overall_status: RECRUITING
phase: NA
sponsor: University Medical Center Groningen
study_type: INTERVENTIONAL
primary_condition: Cancer Survivors
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06769165.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06769165"
ct_last_update_post_date: 2025-12-11
last_seen_at: "2026-05-12T07:17:58.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors

**Official Title:** EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors - a Pilot Study

**NCT ID:** [NCT06769165](https://clinicaltrials.gov/study/NCT06769165)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** University Medical Center Groningen
- **Conditions:** Cancer Survivors
- **Start Date:** 2025-07-02
- **Completion Date:** 2026-08-01
- **CT.gov Last Update:** 2025-12-11

## Brief Summary

To explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.

## Detailed Description

Conditioned nausea and vomiting is a common side effect of anti-cancer treatment, and while strategies like antiemetics exist, their effectiveness is limited. Conditioned nausea and vomiting can possibly be addressed through Eye Movement Desensitization and Reprocessing (EMDR) therapy. EMDR therapy is a therapeutic intervention, proven to be effective in the treatment of post-traumatic stress disorder (PTSD), and promising in treating a range of other conditions. At the UMCG, EMDR therapy is used on a small scale to treat conditioned nausea with positive results, although more rigorous research is needed to fully establish its efficacy. This study aims to explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.

## Eligibility

- **Minimum age:** 16 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Previously pathologically confirmed diagnosis of cancer
* Previously treated with systemic cancer therapy
* Persistent complaints (more than 2 months) of conditioned nausea and/or vomiting
* Able to understand spoken and written Dutch
* 18 years or older

Exclusion Criteria:

* Ongoing psychiatric treatment
* EMDR therapy contraindications (dissociative disorders, personality disorders or severe somatic disorders (e.g. cardiac arrhythmias))
* Complex type 2 trauma
* Known with recent conditions / non-anti-cancer medication which can elicit nausea (e.g. pregnancy or alcohol abuses)
```

## Arms

- **EMDR Therapy** (EXPERIMENTAL) — EMDR therapy sessions with a trained psychologist.

## Interventions

- **EMDR therapy** (OTHER) — In this study, EMDR therapy will be performed by psychologists of the UMCG who are trained in EMDR therapy and who have experience with patients with somatic diseases. In the EMDR therapy protocol, the patient is guided through eight phases which incorporate dual focus of attention and alternating bilateral visual, auditory, and/or tactile stimulation (see supplement for protocol). The number of sessions varies per patient (1-3 sessions), depending on the desensitization of the conditioned stimuli. The sessions will last 60-90 minutes.

## Primary Outcomes

- **Degree of conditioned nausea and vomiting** _(time frame: Before intake EMDR therapy session and three weeks after last EMDR therapy session)_ — Degree of conditioned nausea and vomiting after exposure to conditioned stimuli using the nausea profile questionnaire measured using the nausea profile questionnaire (9-point Likert scale, higher scores = worse outcome)

## Secondary Outcomes

- **Impact on QoL of conditioned nausea and vomiting** _(time frame: Before EMDR therapy)_

## Locations (1)

- University Medical Center Groningen, Groningen, Provincie Groningen, Netherlands — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university medical center groningen|groningen|provincie groningen|netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06769165.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06769165*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*